An observational study on the incidence of HER-2/neu receptor over-expression and comparison of clinical presentation between HER-2/neu positive and HER-2/neu negative breast cancer

Authors

  • Sajib Chatterjee Department of General Surgery, Nil Ratan Sircar Medical College and Hospital, Kolkata, India
  • Madan Mohan Mukherjee Department of General Surgery, Nil Ratan Sircar Medical College and Hospital, Kolkata, India
  • Nemai Chandra Nath Department of General Surgery, Nil Ratan Sircar Medical College and Hospital, Kolkata, India
  • Saugata Samanta Department of General Surgery, Nil Ratan Sircar Medical College and Hospital, Kolkata, India
  • Asis Kumar Saha Department of General Surgery, Nil Ratan Sircar Medical College and Hospital, Kolkata, India

DOI:

https://doi.org/10.18203/2349-2902.isj20170073

Keywords:

Breast cancer, Chemotherapy, HER-2/neu receptor

Abstract

Background:Tumours that over express HER2/neu are less responsive to chemotherapy and patients with these tumours have a reduced survival compared with patients with normal levels of HER2/neu. The aim was to determine the frequency of HER-2/neu receptor over-expression in Breast cancer patients and its comparison to Her-2/neu negative breast cancer in respect to clinical presentation, risk factors, clinical staging, pathological staging.

Methods: 50 patients who presented with Invasive ductal carcinoma of breast, meeting inclusion and exclusion criteria were included in the study. They were divided into two groups; according to Her-2/neu receptor over-expression (Yes/No).Incidence of Her-2-neu receptor over-expression was determined among the sample population. Both groups were compared on the basis of various parameters.

Results: Young age at presentation, negative hormone receptor status (ER/PR), high grade of tumour, large sized tumour and increased axillary lymph nodes are more common in Her-2/neu over-expression patients. These parameters are statistically significant.

Conclusions: Her-2/neu overexpressing breast cancers have increased invasive and metastatic capability and are less responsive to chemotherapy. They have increased risk of recurrence and patients with these tumours have a reduced survival compared with patients with normal levels of HER2/neu.

References

Sariego J. Breast cancer in the young patient. Am Surg. 2010;76(12):1397-401.

International agency for research on cancer. World Cancer Report. 2008.

Slamon DJ, Clark GM. Amplification of C-ERB-B2 and aggressive breast tumours? Science. 1988;240:1795-8.

Potter CR. The neuoncogene: more than a prognostic indicator? Hum Pathol. 1994;25:1264-8.

Lupu R, Cardillo M, Harris L. Interaction between ERB-receptors and here gulin in breast cancer tumour progression and drug resistance. Sem Cancer Biol. 1995;6:135-45.

Slamon DJ, Clark GM, Wong SG. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177-82.

Slamon DJ, Godolphini W, Jones LA. Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science. 1989;244:707-12.

Mohon MB. Bull WHO. 1970;43:209-17.

Olsson H, Borg A, Ferno M, Ranstam J, Sigurdsson H. Her-2/neu and INT2 proto-oncogene amplification in malignant breast tumours in relation to reproductive factors and exposure to exogenous hormones. J Natl Cancer Inst. 1991;83:1483-7.

Gammon MD, Hibshoosh H, Terry MB, Bose S, Schoenberg JB, Brinton LA, et al. Thompson. ocp use and other risk factors in relation to Her-2/neu over expression in breast cancer among young women. Breast J. 2005;11:278-80.

Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Rosaria B, Alessandro T. Prognostic significance of her-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer. 1991;49(1):44-9.

Khorshid MR, Ahmed AW, Emad EG. Prognostic significance of HER2/neu oncogene in breast cancer patients. Scientific Annual Report. 2000;2:2-6.

Moundhri M, Nirmala V, Mawaly K. Significance of P53, Bcl2, and HER2/neu protein expression in Omani arab females with breast cancer. Pathol Oncol Res. 2003;9:226-31.

Tariq S, Salam A, Kiran S, Moinuddin SJ, K Shaista, Kayani N. The clinical pattern of Her-2/neu oncogene over expressing breast cancer at initial presentation. Cancer Res. 1999;52:294-9.

Alahwal MS. HER-2 positivity and correlations with other histopathologic features in Breast Cancer patients–hospital based study. J Pak Med Assoc. 2006;56:65-8.

Almasri NM, Hamad M. Immuno histochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptor in breast carcinoma in Jordan. Breast Cancer Res. 2005;7:598-604.

Hoff ER, Tubbs RR, Myles JL, Procop GW. HER-2/neu amplification in breast cancer. Stratification by tumor type and grade. Am J Clin Pathol. 2002;49:110-3.

Tokatli F, Altaner S, Uzal C, Ture M, Kocak Z, Uygun K, et al. Association of HER-2/neu overexpression with the number of involved axillary lymph nodes in hormone receptor positive breast cancer patients. Exp Oncol. 2005;27:145-9.

Muss HB, Thor AD, Berry DA. Cerb-B2 expression and response to adjuvant therapy in women with node-positive early breast cancer. N Engl J Med. 1994;330:1260-6.

Stahl O, Sullivan S, Wingren S. C-erbB2 expression and benefit from adjuvant chemotherapy and radiotherapy of breast cancer. Eur J Cancer. 1995;31:218-9.

Revillion F, Hebbar M, Boneterre J. Plasma CerbB2 concentrations in relations to chemotherapy in breast cancer patients. Eur J Cancer. 1996;32:231-4.

Downloads

Published

2017-01-25

Issue

Section

Original Research Articles